Sihuan Pharmaceutical Announces HK$500 Million Share Repurchase Plan

An announcement from Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) is now available.

Sihuan Pharmaceutical Holdings Group Ltd. has announced a share repurchase plan of up to HK$500 million, reflecting its confidence in the company’s future prospects and commitment to enhancing shareholder value. This move aligns with its strategic goals, as the company continues to expand its medical aesthetics and biopharmaceutical businesses, with significant growth reported in its medical aesthetics segment and several new product approvals expected to boost revenue.

More about Sihuan Pharmaceutical Holdings Group

Sihuan Pharmaceutical Holdings Group Ltd., founded in 2001 and listed on the Main Board of the Stock Exchange in 2010, is an international company focused on medical aesthetics and biopharmaceuticals. It is recognized for its innovation, possessing a leading research and development technology platform, a comprehensive product pipeline, and a robust sales system. The company aims to become a leader in the medical aesthetics and biopharmaceutical sectors in China.

YTD Price Performance: 142.00%

Average Trading Volume: 200

Technical Sentiment Signal: Sell

Current Market Cap: $866.1M

For an in-depth examination of 0460 stock, go to TipRanks’ Stock Analysis page.